Movement Alert｜CanNova Bio Rises 10.01% in Regular Trading, Receives First-Time Buy Rating from Shenwan Hongyuan

Market Focus

05/29

On May 29, CanNova Bio rose 10.01% in regular trading, trading at HK$63.2 per share, with trading volume of HK$112 million.

On the news front, Shenwan Hongyuan Securities initiated coverage on CanNova Bio with a Buy rating and a target price of HK$89.47, implying 48% upside. The research report highlighted that the core product Sipuqibai monoclonal antibody has received approval for three indications, all of which have been included in the National Medical Insurance Directory. Drug sales revenue reached RMB 315 million in 2025, representing a 776% year-over-year increase. Additionally, the company's NewCo partner was acquired by Gilead Sciences, entitling CanNova Bio to receive approximately US$250 million in upfront payments.

The broader biotech sector rallied on the same day, with Innovent Bio up 12.29%, 3SBio up 9.04%, Akeso up 8.15%, and Remegen up 6.21%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1142232953"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142232953\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142232953?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 13:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142232953","market":"us","top_or_hot":-1,"title":"Movement Alert｜CanNova Bio Rises 10.01% in Regular Trading, Receives First-Time Buy Rating from Shenwan Hongyuan","media":"Market Focus","content":"<p><p>On May 29, CanNova Bio rose 10.01% in regular trading, trading at HK$63.2 per share, with trading volume of HK$112 million.</p><p>On the news front, Shenwan Hongyuan Securities initiated coverage on CanNova Bio with a Buy rating and a target price of HK$89.47, implying 48% upside. The research report highlighted that the core product Sipuqibai monoclonal antibody has received approval for three indications, all of which have been included in the National Medical Insurance Directory. Drug sales revenue reached RMB 315 million in 2025, representing a 776% year-over-year increase. Additionally, the company's NewCo partner was acquired by Gilead Sciences, entitling CanNova Bio to receive approximately US$250 million in upfront payments.</p><p>The broader biotech sector rallied on the same day, with Innovent Bio up 12.29%, 3SBio up 9.04%, Akeso up 8.15%, and Remegen up 6.21%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CanNova Bio Rises 10.01% in Regular Trading, Receives First-Time Buy Rating from Shenwan Hongyuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CanNova Bio Rises 10.01% in Regular Trading, Receives First-Time Buy Rating from Shenwan Hongyuan\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-05-29 13:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On May 29, CanNova Bio rose 10.01% in regular trading, trading at HK$63.2 per share, with trading volume of HK$112 million.</p><p>On the news front, Shenwan Hongyuan Securities initiated coverage on CanNova Bio with a Buy rating and a target price of HK$89.47, implying 48% upside. The research report highlighted that the core product Sipuqibai monoclonal antibody has received approval for three indications, all of which have been included in the National Medical Insurance Directory. Drug sales revenue reached RMB 315 million in 2025, representing a 776% year-over-year increase. Additionally, the company's NewCo partner was acquired by Gilead Sciences, entitling CanNova Bio to receive approximately US$250 million in upfront payments.</p><p>The broader biotech sector rallied on the same day, with Innovent Bio up 12.29%, 3SBio up 9.04%, Akeso up 8.15%, and Remegen up 6.21%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康諾亞-B","start_time":0,"source_url":"","article_id":"1142232953","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142232953","pubTimestamp":1780034063,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 29, CanNova Bio rose 10.01% in regular trading, trading at HK$63.2 per share, with trading volume of HK$112 million.On the news front, Shenwan Hongyuan Securities initiated coverage on CanNova...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"动静提示|康诺生物常规交易涨10.01%获申万宏源首次买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"On May 29, CanNova Bio rose 10.01% in regular trading, trading at HK$63.2 per share, with trading volume of HK$112 million.On the news front, Shenwan Hongyuan Securities initiated coverage on CanNova Bio with a Buy rating and a target price of HK$89.47, implying 48% upside. The research report highlighted that the core product Sipuqibai monoclonal antibody has received approval for three indications, all of which have been included in the National Medical Insurance Directory. Drug sales revenue reached RMB 315 million in 2025, representing a 776% year-over-year increase. Additionally, the company's NewCo partner was acquired by Gilead Sciences, entitling CanNova Bio to receive approximately US$250 million in upfront payments.The broader biotech sector rallied on the same day, with Innovent Bio up 12.29%, 3SBio up 9.04%, Akeso up 8.15%, and Remegen up 6.21%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}